Hanhsing Wu, MD
Hematology & Oncology · Mountain View, CANPI 1114034832
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $295 of the $368 with a category attached, or 80.1%. It is spread thinly across 12 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $279, more than ten times the $12 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 15 payments — averaging $24.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$63
- Pfizer$61
- E.r. Squibb & Sons, L.L.C.$32
- Eisai Inc.$31
- Genentech USA, Inc.$30
- AbbVie$29
- plus $122 from 6 others
What the payments were for
- Food & beverage$29580%
- Education$7320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 2 | $63 |
| Pfizer | 3 | $61 |
| E.r. Squibb & Sons, L.L.C. | 1 | $32 |
| Eisai Inc. | 1 | $31 |
| Genentech USA, Inc. | 1 | $30 |
| AbbVie | 1 | $29 |
| Incyte Corporation | 1 | $27 |
| Array Biopharma Inc | 1 | $25 |
| GSK | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Genmab U.S., Inc. | 1 | $18 |
| Seagen Inc. | 1 | $12 |
How this compares
$368 in reported general payments places this provider in the 20th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 21 | $327,524 |
| VerzenioAbemaciclib | 12 | $204,276 |
| RevlimidLenalidomide | 14 | $165,145 |
| GilotrifAfatinib Dimaleate | 12 | $136,830 |
| Anastrozole | 213 | $4,889 |
| Exemestane | 17 | $4,163 |
| Letrozole | 73 | $2,202 |
| Tamoxifen Citrate | 72 | $1,851 |
| Alendronate Sodium | 115 | $1,324 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $812 |
| Dexamethasone | 20 | $476 |
| Prochlorperazine Maleate | 31 | $450 |
| Prednisone | 47 | $372 |
| Levothyroxine Sodium | 23 | $321 |
| Acyclovir | 13 | $248 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Mountain View
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.